TGA introduces shorter Surveillance Inspections
Recommendation
10-12 November 2026
Hamburg, Germany
An advanced Auditor Course with many interactive Sessions and practical Examples
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
From 1 July 2024, the Australian TGA will introduce, at least temporarily, new regulations for GMP inspections of domestic and foreign manufacturers of medicinal products, active pharmaceutical ingredients (APIs), biological products and blood products, so-called surveillance inspections.
These are repeat inspections of manufacturers with a shorter duration, but according to the TGA with full scope. This means that the inspection should cover all aspects of the pharmaceutical quality system (PQS) and the operations, but be reduced by around 50 % of the usual inspection time.
The GMP certificates issued after the inspection will then state that a surveillance inspection has been carried out.
Who is eligible for this?
Both domestic and foreign manufacturers who received a "good" or "satisfactory" rating (A1 or A2) in their last TGA inspection. However, there are also clearly defined exceptions where shortened inspections are not possible.
Objectives
The primary aim is to reduce overdue re-inspections to a level commensurate with the manufacturer's risk and to reduce business disruption caused by delays in re-inspections.
Related GMP News
26.10.2026Inadequate Supplier Oversight and missing Tests: Lessons from an FDA Warning Letter
21.10.2026FDA Cites Serious CGMP Deficiencies at Stream2Sea
23.09.2026FDA Inspection as GMP Evidence? Swissmedic Opens Up a New Option
23.09.2026New: Coordination of GMP Inspections for Centrally Authorised Products
16.09.2026How GMP Non-Compliance can stop a Marketing Authorisation Application
10.09.2026FDA Warning Letter: Inadequate Warehouse Controls and Lot Traceability